Overview

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Treatments:

Hormones
Radium Ra 223 dichloride
Succinylcholine